Shots:

• AstraZeneca to receive up to $181M up front and sales-contingent payments of up to $17M. Juisve to get exclusive commercialization rights for Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European- African and other countries
• Additionally- in 2017 AstraZeneca divested its rights of Arimidex and Casodex in the US and the therapies have lost their patent protection in above-mentioned countries targeted to treat breast and prostate cancers
• Arimidex (anastrozole) is an aromatase inhibitor targeted to treat multiple indications of cancer and has generated sales of $37M in 2018. Casodex (bicalutamide) is an androgen-receptor inhibitor administered in combination with a luteinizing hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate

Click here to read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca